People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $150.9M | $3.3B | 2018 |
Natarajan Sethuraman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Natarajan Sethuraman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Todd Foley | 1 | 12 |
| Kush Parmar | 1 | 10 |
| KUSH M. PARMAR | 1 | 3 |
| Christine Brennan | 1 | 3 |
| Louis Tartaglia | 1 | 3 |
| John F. Crowley | 1 | 2 |
| Mario Saltarelli | 1 | 2 |
| Anja Harmeier | 1 | 2 |
| John Crowley | 1 | 2 |
| Nathan Dowden | 1 | 1 |
| Dehua Pei | 1 | 1 |
| Carole F. Nuechterlein | 1 | 1 |
| Natarajan F. Sethuraman | 1 | 1 |
| Todd F. Foley | 1 | 1 |
| Peter F. Kim | 1 | 1 |
| Nerissa F. Kreher | 1 | 1 |
| Kory F. Wentworth | 1 | 1 |
| Dipal Doshi | 1 | 1 |
| Nathan F. Dowden | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.